Merus N.v.

  • Health Care
  • Biotechnology: Pharmaceutical Preparations
  • www.merus.nl
  • Moat Score
  • Market Cap $3.42B
  • PE -14
  • Debt $NaN
  • Cash $433.77M
  • EV $NaN
  • FCF -$157.15M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$244.56M
EBIT-$237.13M
ROE-35%
ROA-28%
FCF-$157.15M
Equity$703.26M
Growth Stability1
PE-13.98
PB4.86
P/FCF-21.75
P/S95.13
Price/Cash0.13
Net Margins-683%
Op. Margins-660%
Sales Growth YoY7%
Sales Growth QoQ61%
Sales CAGR7%
Equity CAGR40%
Earnings Growth YoY334%
Earnings Growth QoQ100%
Sales CAGR 5Y7%
Equity CAGR 5Y42%
Earnings CAGR 3Y-12%
Sales CAGR 3Y-12%
Equity CAGR 3Y32%
Market Cap$3.42B
Revenue$35.93M
Assets$844.68M
Cash$433.77M
Shares Outstanding62.72M
Moat Score1%
Working Capital586.2M
Current Ratio8.32
Shares Growth 3y17%
Equity Growth QoQ-6%
Equity Growth YoY79%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

SEC Filings

Direct access to Merus N.v. (MRUS) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Merus N.v. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Merus N.v. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Merus N.v. Discounted Cash Flow

Fully customizable DCF calculator online for Merus N.v..

= -$1.6B
012345678910TV
fcf-$157M-$157M-$157M-$157M-$157M-$157M-$157M-$157M-$157M-$157M-$157M-$1.6B
DCF-$143M-$130M-$118M-$107M-$98M-$89M-$81M-$73M-$67M-$61M-$606M
Value-$1.6B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201812/201912/202012/202112/202212/2023TTM
Net Margins-74%-177%-286%-136%-315%-353%-683%
ROA--21%-33%-15%-35%-33%-28%
ROE--42%-84%-21%-53%-43%-35%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201812/201912/202012/202112/202212/2023TTM
Debt over FCF-------
Debt over Equity-------
Growth Stability------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth--19%-4%64%-15%6%7%
Earnings YoY growth-95%55%-22%96%18%-
Equity YoY growth-24%-22%209%-22%44%42%
FCF YoY growth-36%24%-25%160%-7%-